Brainomix joins forces with Boehringer Ingelheim to help save stroke victims
Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
Brainomix – International Journal of Stroke Publication
Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from ischemic stroke patients were evaluated by e-ASPECTS and… Read More
Brainomix – Parkwalk closes follow-on investment
We have recently closed an investment in Brainomix for the Parkwalk UK Tech Fund VII and the Opportunities Fund. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses… Read More
Brainomix – receives Biomedical Catalyst funding to develop clinical decision-making software for stroke patients
Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The… Read More
Brainomix – Positive endovascular trial uses ASPECTS
A seminal paper was published in the New England Journal of Medicine describing the results of the ESCAPE trial for endovascular treatment of stroke patients. This study shows that rapid endovascular treatment leads to significantly improved functional outcomes… Read More
Brainomix – wins ACES award for ICT
University of Oxford Isis Fund I and Parkwalk portfolio company Brainomix wins ACES entrepreneurship prize which rewards companies working in health and environment: BERLIN – 7 October 2014. Spin-outs from Germany, Switzerland and the UK won the ACES… Read More
Brainomix – University of Oxford Isis Fund I and Parkwalk investment
We have recently closed an investment in Brainomix for the University of Oxford Isis Fund I and Parkwalk Funds. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for… Read More
